Results 121 to 130 of about 41,944 (264)

PARP inhibitors in ovarian cancer [PDF]

, 2016
BACKGROUND: Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy.
Ledermann, JA
core   +1 more source

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Annals of Oncology
BACKGROUND Use of first-line PARP inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression in the first-line setting is important to ...
P. Harter, C. Marth, M-A. Mouret-Reynier, C. Cropet, D. Lorusso, E. Guerra-Alía, T. Matsumoto, I. Vergote, N. Colombo, J. Mäenpää, C. Lebreton, N. de Gregorio, A. Mosconi, M. Rubio-Pérez, H. Bourgeois, P. Fasching, S. Cecere, A. Hardy-Bessard, D. Denschlag, S. de Percin, L. Hanker, L. Favier, D. Bauerschlag, C. Desauw, P. Hillemanns, R. Largillier, J. Sehouli, J. Grenier, E. Pujade-Lauraine, I. Ray-Coquard   +29 more
semanticscholar   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma [PDF]

, 2017
High-grade epithelial ovarian carcinomas (OC) containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi), while restoration of HR ...
Barker, Holly, Bernstein, Kara A., Botwell, David D.L., Brunette, Gregory J., Coleman, Robert L., Floquet, Anna, Friedlander, Michael, Giordano, Heidi, Harding, Thomas C., Harrell, Maria I., Ho, Gwo-Yaw, Jasin, Maria, Kass, Elizabeth M., Kaufmann, Scott H., Kichenadasse, Ganessan, Kondrashova, Olga, Kuiper, Michael J., Lin, Kevin K., Maloney, Lara, McNeish, Iain A., Nguyen, Minh, O'Malley, David M., Oza, Amit M., Prakash, Rohit, Raponi, Mitch, Robillard, Liliane, Scott, Clare L., Shield-Artin, Kirsty, Simmons, Andrew D., Sullivan, Meghan R., Sun, James X., Swisher, Elizabeth M., Teng, Nelson N.H., Tinker, Anna V., Wakefield, Matthew J.   +34 more
core   +1 more source

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

Nature Communications
Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity.
G. Freyer, A. Floquet, O. Tredan, A. Carrot, C. Langlois-Jacques, Jonathan Lopez, F. Selle, C. Abdeddaim, A. Leary, Coraline Dubot-Poitelon, Michel Fabbro, L. Gladieff, M. Lamuraglia   +12 more
semanticscholar   +1 more source

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin [PDF]

, 2016
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al.Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors
Amaral, Ana Teresa, Fraile, Susana, García-Macías, Carmen, Herrero-Martín, David, Mora, Jaume, Ordóñez, José Luis, San-Segundo, Laura, Sevillano, Victoria, Teodosio, Cristina, Tirado, Óscar M., Álava, Enrique de   +10 more
core   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease [PDF]

, 2016
HIGHLIGHTS: Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer; A clinically significant dose of olaprib is able to penetrate the leptomeninges; Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to ...
Bangham, M, Goldstein, R, Ledermann, JA, Walton, H   +3 more
core   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, EarlyView.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers [PDF]

, 2014
Inhibition of poly(ADP-ribose) polymerase (PARP) is a promising therapeutic strategy for BRCA1 deficient cancers, however, the development of drug resistance limits clinical efficacy.
Chen, Qianming, Hu, Mickey C T, Huang, Yuping, Pandita, Tej K, Sun, Chong-kui, Xiang, Tao, Yang, Qin, Zhang, Fan   +7 more
core   +3 more sources